Company Overview - Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][3] - The company has two drug candidates in its pipeline: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] Upcoming Event - Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025, at 12:30 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2] Intellectual Property - Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [3]
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit